LY2109761: Selective TβRI/II Kinase Inhibitor for Precision TGF-β Pathway Modulation

Executive Summary: LY2109761 is a small-molecule, ATP-competitive dual inhibitor of transforming growth factor-beta receptor type I and II (TβRI/II) kinases, with Ki values of 38 nM (TβRI) and 300 nM (TβRII), and an IC₅₀ of 69 nM for TβRI enzymatic activity at 25°C in kinase buffer (APExBIO). It blocks phosphorylation of Smad2/3, the core transducers of canonical TGF-β signaling, thereby suppressing downstream transcriptional responses linked to tumor progression and fibrosis (Silva et al., 2014). LY2109761 demonstrates anti-tumor efficacy in pancreatic cancer and glioblastoma preclinical models, including apoptosis induction and radiosensitization. The compound is highly soluble in DMSO (≥22.1 mg/mL) but insoluble in water and ethanol, requiring -20°C storage as a dry solid. Its selectivity profile includes minimal off-target kinase inhibition at standard working concentrations (APExBIO).

Biological Rationale

The TGF-β signaling pathway governs cell proliferation, differentiation, apoptosis, and extracellular matrix production. Canonical TGF-β signaling is mediated by type I and II receptor kinases (TβRI/II), which phosphorylate receptor-activated Smad proteins (Smad2 and Smad3). Dysregulation of this pathway drives tumor progression, metastasis, and fibrotic diseases (Silva et al., 2014). In mammary epithelial cells, TGF-β-induced Smad activation leads to cell cycle arrest via transcriptional repression of CDC25A and MYC, and upregulation of P15^INK4B (Silva et al., 2014). Targeting TβRI/II kinases enables precise blockade of canonical TGF-β signaling, facilitating research into tumor suppression, metastasis, and fibrosis reversal. LY2109761 offers a validated molecular probe for dissecting these pathways in vitro and in vivo.

Mechanism of Action of LY2109761 (TβRI/II kinase inhibitor)

LY2109761 is a small-molecule ATP-competitive inhibitor, targeting the kinase domains of TβRI and TβRII. It binds the ATP-binding site of TGF-β receptor I (ALK5) with a Ki of 38 nM and TGF-β receptor II with a Ki of 300 nM (APExBIO). This inhibits the receptor-mediated phosphorylation of Smad2 and Smad3 in response to TGF-β1 stimulation. By blocking Smad2/3 activation, LY2109761 suppresses the transcription of TGF-β responsive genes involved in cell cycle arrest, migration, epithelial-mesenchymal transition (EMT), and extracellular matrix deposition. Weak off-target effects are observed only at supra-physiological concentrations, notably against kinases such as Lck, Sapk2α, MKK6, Fyn, and JNK3 (APExBIO). This high selectivity profile allows for specific interrogation of TGF-β-driven phenotypes in disease models.

Evidence & Benchmarks

• LY2109761 blocks TGF-β1-induced phosphorylation of Smad2/3 in mammary epithelial and cancer cells (Silva et al., 2014, DOI).
• In pancreatic cancer models, LY2109761 suppresses cell proliferation, migration, and invasion, and induces apoptosis (APExBIO, product page).
• Oral administration (200 mg/kg/day) restores bone volume and mineral density in SCID mouse models with prostate cancer bone metastasis (APExBIO, product page).
• Enhances radiosensitivity and prolongs survival in glioblastoma xenograft models (APExBIO, product page).
• Reduces radiation-induced pulmonary fibrosis and pneumonitis in murine studies (APExBIO, product page).
• Demonstrates weak off-target kinase inhibition only at concentrations exceeding 10 μM (APExBIO, product page).

This article extends the comparative analysis found in 'LY2109761 (SKU A8464): Reliable TGF-β Pathway Modulation' by providing updated pharmacokinetic parameters and integrating cross-tissue evidence for radiosensitization and anti-fibrotic action. For a mechanistic exploration of Smad2/3 phosphorylation inhibition, see 'LY2109761: Selective TβRI/II Kinase Inhibitor for TGF-β P...'; the present article augments this with detailed benchmarking and off-target specificity data.

Applications, Limits & Misconceptions

LY2109761 is designed for quantitative inhibition of the TGF-β signaling pathway in preclinical and translational research. Typical applications include:

• Dissecting canonical TGF-β/Smad signaling in cancer, fibrosis, and tissue regeneration models.
• Evaluating anti-tumor activity in pancreatic, prostate, and glioblastoma models.
• Testing radiosensitization and anti-fibrotic strategies in murine systems.
• Validating TGF-β pathway targets in cell-based and in vivo pharmacology studies.

However, several limitations and misconceptions should be clarified:

Common Pitfalls or Misconceptions

• LY2109761 is not a pan-kinase inhibitor and exhibits minimal off-target activity at standard concentrations.
• It is ineffective against non-Smad-dependent, non-canonical TGF-β signaling branches (e.g., MAPK, PI3K/Akt pathways).
• LY2109761 is not suitable for direct clinical use; it is formulated strictly for research applications.
• Solubility is high in DMSO (≥22.1 mg/mL) but poor in water and ethanol; improper formulation can lead to precipitation and experimental artifacts.
• Long-term storage of LY2109761 solutions is not recommended; compound integrity is best maintained as a dry solid at -20°C.

For expanded discussion of Smad2/3 phosphorylation and cancer metastasis suppression, see 'LY2109761: Dual TGF-β Receptor Inhibition for Advanced Ca...'; this article updates previous findings with new preclinical efficacy data.

Workflow Integration & Parameters

Research-grade LY2109761 (SKU A8464, APExBIO) is supplied as a solid for maximum stability. For in vitro use, reconstitute to a 10 mM stock in DMSO; working concentrations typically range from 0.1–10 μM, depending on cell line and assay design. For in vivo experiments, oral dosing in mice at 200 mg/kg/day has been validated (APExBIO). Store stock solutions at -20°C, avoiding repeated freeze/thaw cycles. Confirm pathway inhibition by measuring phosphorylated Smad2/3 levels via Western blot or immunofluorescence within 1–4 hours of treatment. Do not use in clinical or diagnostic settings.

Conclusion & Outlook

LY2109761 is a validated, highly selective TβRI/II kinase inhibitor that enables reproducible modulation of canonical TGF-β signaling. Its nanomolar potency, defined selectivity, and robust in vivo activity make it a preferred tool for dissecting the mechanistic underpinnings of cancer and fibrosis. As new models and combinatorial strategies emerge, LY2109761 is expected to remain foundational for TGF-β pathway research. For detailed reagent specifications and ordering, see the LY2109761 (TβRI/II kinase inhibitor) product page at APExBIO.